{"id":"W3126738486","doi":"10.1200/jco.20.02365","title":"Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":287,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre; Université Laval","funders":"National Cancer Institute","keywords":"Medicine; Pembrolizumab; Chromophobe cell; Internal medicine; Renal cell carcinoma; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Clinical endpoint; Histology; Phases of clinical research; Cohort; Clear cell; Surgery; Oncology; Urology; Cancer; Chemotherapy; Immunotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001472385,0.001169875,0.002073131,0.0003808382,0.0004283593,0.001180516,0.0007619907,0.001068848,0.003434546],"category_scores_gemma":[0.001012691,0.0006123523,0.0008534734,0.0003092439,0.0008337987,0.001190484,0.0002913873,0.003217367,0.001010968],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009723243,"about_ca_system_score_gemma":0.00150687,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006384745,"about_ca_topic_score_gemma":0.001891188,"domain_scores_codex":[0.9995752,0.0001687904,0.00002262613,0.0001072883,0.00004967399,0.00007641863],"domain_scores_gemma":[0.9991554,0.0001129579,0.0001383092,0.00006596277,0.0000628299,0.000464483],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.751015,0.1436371,0.009526659,0.0006794595,0.001294992,0.0001934842,0.0003468568,0.001429237,0.02956793,0.0001779658,0.002904891,0.05922636],"study_design_scores_gemma":[0.6410744,0.3374127,0.01666069,0.0000235053,0.0002452469,0.0001682955,0.00005696342,0.001303766,0.001407801,0.0001241331,0.001500526,0.00002201663],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952905,0.001111375,0.0003076714,0.0002457754,0.0000901262,0.001483213,0.0005711908,0.00004742153,0.000852771],"genre_scores_gemma":[0.9935981,0.0006893741,0.0009000887,0.0005812063,0.0001530586,0.001606804,0.0009791686,0.00001417606,0.001478039],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003434546,"threshold_uncertainty_score":0.01148969,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1156760804025165,"score_gpt":0.4254655043625331,"score_spread":0.3097894239600166,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}